Medscape Hematology-Oncology Headlines This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
All In: Two Cancers, One Surgical Team Who's Not Giving Up All In: Two Cancers, One Surgical Team Who's Not Giving Up
Surgeons know not to count on miracles, but sometimes they can happen. Our cameras follow a surgical team as they work together to treat a patient with an uncertain outcome.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 15, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
This Frontline Therapy Is Better in Multiple Myeloma: Study This Frontline Therapy Is Better in Multiple Myeloma: Study
A study directly comparing real-world outcomes suggests patients with transplant-ineligible multiple myeloma do better with frontline triple therapy with daratumumab vs bortezomib.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer Survival-Toxicity Trade-off With T-DM1 in HER+ Breast Cancer
Older patients with advanced HER2+ breast cancer do not experience a survival benefit with trastuzumab emtansine vs standard-of-care combination therapy, although toxicity is improved, a trial shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Bluebird Signs Pact With Insurer for Sickle Cell Gene Therapy Bluebird Signs Pact With Insurer for Sickle Cell Gene Therapy
Bluebird bio said on Thursday a large insurer had agreed to cover its newly approved sickle cell disease gene therapy, easing some investor worries about resistance from...Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
What if a Single GLP-1 Shot Could Last for Months? What if a Single GLP-1 Shot Could Last for Months?
New hydrogel technology could reduce GLP-1 injections from daily or weekly to three times a year.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 14, 2023 Category: Cancer & Oncology Tags: Diabetes & Endocrinology Source Type: news
Less Is More for Axillary Surgery in Early Breast Cancer Less Is More for Axillary Surgery in Early Breast Cancer
Women with early breast cancer can safely undergo less extensive axillary surgery because it has no impact on recurrence or mortality rates but reduces the risk for lymphedema, a meta-analysis shows.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
No Benefit to Salvage Transplant in R/R Multiple Myeloma No Benefit to Salvage Transplant in R/R Multiple Myeloma
Long-term follow-up shows no progression-free or overall survival advantage among patients who received salvage transplant vs continuous lenalidomide plus dexamethasone.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
' Baby Tam' Effective, Tolerable for Breast Cancer Prevention'Baby Tam' Effective, Tolerable for Breast Cancer Prevention
Lower-dose tamoxifen aims to reduce those side effects, but there remains some uncertainty about the minimum dose required to maintain efficacy.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Few With Inflammatory Breast Cancer Get Guideline-Based Care Few With Inflammatory Breast Cancer Get Guideline-Based Care
A US study finds a surprisingly low rate of guideline-concordant care in women with inflammatory breast cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Sickle Cell: Good Outcomes for Haploidentical Transplants Sickle Cell: Good Outcomes for Haploidentical Transplants
It is much easier to find eligible haploidentical donors — half-matched or partially matched — than eligible hematopoietic donors.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Mantle Cell Lymphoma: Drug Combo Improves PFS Mantle Cell Lymphoma: Drug Combo Improves PFS
' In the countries where ibrutinib is indicated, this combination should be a new standard therapy for relapsed/refractory mantle cell lymphoma. 'MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Europe Approves Avapritinib for Rare Mast Cell Disease Europe Approves Avapritinib for Rare Mast Cell Disease
The drug targets a mast cell mutation that gives rise to indolent systemic mastocytosis, a rare and debilitating blood disorder.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Supercharge Your Medical Practice With ChatGPT Supercharge Your Medical Practice With ChatGPT
An expert on artificial intelligence in oncology describes why, and how, to integrate ChatGPT into your clinical practice.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity Myeloma: Isatuximab 4-Drug Regimen Boosts MRD Negativity
' This [research] builds on our experience that four-drug combinations with a monoclonal antibody, proteasome inhibitor, immunomodulatory drug, and steroids are superior to three-drug combinations. 'MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
The Unknowns of Taxanes for Breast Cancer During Pregnancy The Unknowns of Taxanes for Breast Cancer During Pregnancy
Taxane exposure during pregnancy appears to be safe for mothers and offspring, according to a new retrospective cohort analysis.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news